From Foe to Friend in COVID-19: Renin-Angiotensin System Inhibitors.
作者信息
Kidde Jason, Sahebkar Amirhossein
机构信息
Department of Emergency Medicine, University of Utah, Salt Lake City, Utah, USA.
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
出版信息
J Infect Dis. 2021 Jan 4;223(1):174-175. doi: 10.1093/infdis/jiaa629.
Abstract
摘要
相似文献
1
From Foe to Friend in COVID-19: Renin-Angiotensin System Inhibitors.从新冠病毒的“敌人”到“朋友”：肾素-血管紧张素系统抑制剂
J Infect Dis. 2021 Jan 4;223(1):174-175. doi: 10.1093/infdis/jiaa629.
2
Renin-angiotensin system blockers and COVID-19.肾素-血管紧张素系统阻滞剂与新型冠状病毒肺炎
BMC Med. 2021 Jun 4;19(1):136. doi: 10.1186/s12916-021-02012-6.
3
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在 2019 冠状病毒病患者中的应用：是敌是友？
Cardiol Rev. 2020 Jul/Aug;28(4):213-216. doi: 10.1097/CRD.0000000000000319.
4
COVID-19 and the Renin-Angiotensin-Aldosterone System.新型冠状病毒肺炎与肾素-血管紧张素-醛固酮系统
Clin Infect Dis. 2021 Mar 15;72(6):1105-1107. doi: 10.1093/cid/ciaa818.
5
Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and COVID-19: Demonstrating the Actionability of Real-World Evidence.血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂与2019冠状病毒病：展示真实世界证据的可操作性
Am J Hypertens. 2021 Apr 20;34(4):327-329. doi: 10.1093/ajh/hpaa177.
6
Do the Meta-Analyses Provide a Clean Bill of Health to the Use of Renin-angiotensin System Inhibitors in Coronavirus Disease 2019 (COVID-19)?荟萃分析是否为2019冠状病毒病（COVID-19）中使用肾素-血管紧张素系统抑制剂开具了健康证明？
Clin Infect Dis. 2021 Jul 1;73(1):164-165. doi: 10.1093/cid/ciaa1167.
7
Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报6：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2021 Jan;174(1):W17. doi: 10.7326/L20-1355. Epub 2020 Dec 1.
8
Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎患者的预后：一项病例系列研究。
Hypertension. 2020 Aug;76(2):e10-e12. doi: 10.1161/HYPERTENSIONAHA.120.15312. Epub 2020 May 8.
9
Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?肾素-血管紧张素系统调节剂在 COVID-19 合并高血压患者中的应用：是敌是友？
Clin Exp Hypertens. 2022 Jan 2;44(1):1-10. doi: 10.1080/10641963.2021.1963070. Epub 2021 Aug 20.
10
Assessment of ACE inhibitors/angiotensin receptor blockers in COVID-19 patients.评估血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂在新冠肺炎患者中的应用。
Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L37-L38. doi: 10.1152/ajplung.00262.2020.
引用本文的文献
1
Strategies of Pathogens to Escape from NO-Based Host Defense.病原体逃避基于一氧化氮的宿主防御的策略。
Antioxidants (Basel). 2022 Nov 3;11(11):2176. doi: 10.3390/antiox11112176.
2
Lifestyle-mediated nitric oxide boost to prevent SARS-CoV-2 infection: A perspective.生活方式介导的一氧化氮提升预防 SARS-CoV-2 感染：一个视角。
Nitric Oxide. 2021 Oct 1;115:55-61. doi: 10.1016/j.niox.2021.08.001. Epub 2021 Aug 5.
本文引用的文献
1
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.高血压合并 COVID-19 患者住院期间持续使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与临床结局改善相关。
J Infect Dis. 2020 Sep 14;222(8):1256-1264. doi: 10.1093/infdis/jiaa447.
2
Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19.利用一氧化氮预防、限制和治疗 COVID-19 的严重肺部后果。
Nitric Oxide. 2020 Oct 1;103:4-8. doi: 10.1016/j.niox.2020.07.003. Epub 2020 Jul 15.
3
Could nasal nitric oxide help to mitigate the severity of COVID-19?鼻腔一氧化氮能否帮助减轻 COVID-19 的严重程度？
Microbes Infect. 2020 May-Jun;22(4-5):168-171. doi: 10.1016/j.micinf.2020.05.002. Epub 2020 May 6.
4
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
5
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.血管紧张素转化酶抑制剂改善合并高血压的 COVID-19 患者的临床结局。
Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200.
6
Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury.血管紧张素转换酶2（ACE2）介导H7N9流感病毒引起的急性肺损伤。
Sci Rep. 2014 Nov 13;4:7027. doi: 10.1038/srep07027.
7
Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.血管紧张素受体阻滞剂对内皮型一氧化氮合酶释放的影响：eNOS 变异体的作用。
Br J Clin Pharmacol. 2012 Jul;74(1):141-6. doi: 10.1111/j.1365-2125.2012.04189.x.
8
Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected.一氧化氮对严重急性呼吸综合征冠状病毒复制的双重作用：病毒RNA产生和刺突蛋白的棕榈酰化受到影响。
Virology. 2009 Dec 5;395(1):1-9. doi: 10.1016/j.virol.2009.09.007. Epub 2009 Oct 1.
9
Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway.血管紧张素转换酶抑制剂对人血管内皮细胞中内皮素-1与一氧化氮平衡的不同影响：氧化敏感途径的证据
Mediators Inflamm. 2008;2008:305087. doi: 10.1155/2008/305087. Epub 2008 Dec 1.
Zotero 插件